Proprietary Technology Solutions
Accelerate timelines with purpose-built solutions.
MMS is known for its solutions and therapeutic area expertise as a leading, data-focused CRO, but the secret to our success goes deeper. Internal leaders strive for more out of every project, and for us, that often means developing a strong tool, technology, or process. Their curiosity comes alive, as cross-functional teams explore new approaches through the likes of machine learning (ML), natural language processing (NLP), and artificial intelligence (AI).
To accelerate the expertise of our teams, MMS has and continues to develop several proprietary, purpose-built solutions to bring new levels of efficiency and savings to Sponsors.
We welcome you to explore our current technology offerings.
Suggested For You
perspectives
April 8th, 2025
Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements
news
April 3rd, 2025
Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution
perspectives
March 27th, 2025
Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs
news
March 19th, 2025
MMS REMS-focused Technology bolsters Full-Service REMS Solutions
webinar
April 30th, 2025
Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies
perspectives
March 6th, 2025
Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products
webinar
March 25th, 2025
Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success
perspectives
February 13th, 2025
Helping European Drug Development Companies Succeed in the US Market
news
February 12th, 2025
MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO
perspectives
January 30th, 2025
Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned
perspectives
January 21st, 2025
REMS Modifications and Revisions: A Retrospective from the Past 12 Months
regulatory intelligence
January 17th, 2025
The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development